Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization, announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.
Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization, announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.